Richard S. Shames
Keine laufenden Positionen mehr
Profil
Richard S.
Shames worked as a Senior Medical Director at Abbott Biotherapeutics Corp.
from 1999 to 2009, followed by a position as Scientist-Clinical Research at Merck & Co., Inc. from 2009 to 2013.
He then served as Chief Medical Officer at Aldea Pharmaceuticals, Inc. from 2013 to 2015 and later as Chief Medical Officer at Protagonist Therapeutics, Inc. from 2015 to 2019.
Prior to his industry positions, he was an Assistant Clinical Professor-Pediatrics at Stanford University and the University of California.
Shames received his undergraduate degree from Stanford University and his doctorate from the University of California.
Ehemalige bekannte Positionen von Richard S. Shames
| Unternehmen | Position | Ende |
|---|---|---|
| PROTAGONIST THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 09.05.2019 |
Aldea Pharmaceuticals, Inc.
 Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2015 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01.01.2013 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Corporate Officer/Principal | 01.01.2009 |
| University of California | Corporate Officer/Principal | - |
Ausbildung von Richard S. Shames
| University of California | Doctorate Degree |
| Stanford University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| PROTAGONIST THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Aldea Pharmaceuticals, Inc.
Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | Health Technology |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
